Annexon Shares Plummet Amid Phase 3 Trial Updates

Introduction

Annexon Inc (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2011, Annexon focuses on developing a new class of complement therapies that inhibit C1q, the initiating molecule of the classical complement pathway, for the treatment of autoimmune, neurodegenerative, and ophthalmic disorders.

Corporate Structure

Annexon employs approximately 51–200 individuals, supported by a leadership team with experience in drug development and commercialization. Scientific co-founders include Dr. Ben Barres, former Chair of Neurobiology at Stanford University, and Dr. Arnon Rosenthal. In July 2025, Annexon appointed Dr. Lloyd Clark as Senior Vice President of Ophthalmology Strategy & Innovation, bringing over 25 years of clinical and drug-development experience. The Board of Directors includes individuals with backgrounds in biotechnology and investment, overseeing governance, research and development, and financial strategy.

Biopharmaceuticals by little plant

Recent Developments and News

As of July 10, 2025, Annexon shares closed at $2.04, a decrease of 26.35% from the previous day, with a trading volume of 1,924,740 shares on the NASDAQ.

• On June 25, 2025, Annexon filed an 8-K (Accession No. 0001193125-25-147005) reporting Items 3.03 and 9.01, covering governance matters.
• On June 9, 2025, another 8-K (Accession No. 0001193125-25-137810) disclosed information under Item 5.07.
• On May 15, 2025, a Schedule 13G/A amendment indicated that Point72 Asset Management and affiliates beneficially own 95,430 shares, representing approximately 0.1% of the common stock.

In June 2025, at the Peripheral Nerve Society Annual Meeting in Edinburgh, Annexon presented Phase 3 data for tanruprubart (formerly ANX005) in Guillain-Barré Syndrome (GBS), marking the first controlled Phase 3 trial in this indication. The ARCHER II study for geographic atrophy (GA) in dry age-related macular degeneration is currently enrolling participants globally. Annexon is also scheduled to present at the Jefferies Global Healthcare Conference in July 2025.

Financial and Strategic Analysis

Annexon reported a net loss of $167.38 million and diluted EPS of –$1.17 for the trailing twelve months. The company’s market capitalization is approximately $256.73 million, supported by $263.7 million in cash and cash equivalents as of the latest quarter, with debt representing 11.61% of equity. No revenue has been recognized to date.

Annexon's pipeline includes:

• ANX005 (intravenous), currently in a Phase 3 pivotal program for GBS with Orphan Drug Designation from the EMA.
• ANX007 (intravitreal), which demonstrated statistically significant, dose-dependent visual preservation in a Phase 2 trial for geographic atrophy.
• ANX009 (subcutaneous), which has achieved full target engagement in healthy volunteers.
• ANX1502, which has met pharmacokinetic targets in a Phase 1 study.

The company has communicated that it will not provide expanded access to its investigational therapies outside of clinical trials in order to focus on completing its development and regulatory approval processes.

Market Position and Industry Context

Annexon operates within the complement-therapy sector, addressing both rare diseases such as GBS and broader ophthalmic markets like geographic atrophy. By targeting C1q at the top of the classical complement pathway, the company aims to inhibit downstream damaging components, differentiating its strategy from competitors focused on later pathway elements. The company’s success will depend on demonstrating safety and efficacy in ongoing pivotal trials while securing FDA and global regulatory approvals in a highly regulated biotechnology landscape.

tl;dr

On July 10, 2025, ANNX shares closed at $2.04, down 26.35%. Key regulatory filings include an 8-K on June 25 and a Schedule 13G/A on May 15 indicating 0.1% ownership by Point72. In June 2025, Annexon presented Phase 3 data for ANX005 in Guillain-Barré Syndrome at the Peripheral Nerve Society meeting and initiated global enrollment for the ARCHER II study for geographic atrophy. The company will also present at the Jefferies Global Healthcare Conference in July 2025, with top-line results from its Phase 3 GBS program anticipated by year-end 2025.